# Antibiotic Combination for H. Pylori Eradication in Penicillin-allergic Patients

> **NCT05023577** · PHASE4 · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 504 (estimated)

## Conditions studied

- Helicobacter Pylori Infection

## Interventions

- **DRUG:** Rabeprazole
- **DRUG:** Bismuth potassium citrate
- **DRUG:** Metronidazole
- **DRUG:** Clarithromycin
- **DRUG:** Levofloxacin

## Key facts

- **NCT ID:** NCT05023577
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-26
- **Primary completion:** 2022-12-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 504 (ESTIMATED)
- **Last updated:** 2021-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05023577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05023577, "Antibiotic Combination for H. Pylori Eradication in Penicillin-allergic Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05023577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*